Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof. Craddock covers the utility of MRD in determining risk of relapse following induction therapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
MRD to determine risk of relapse after induction in AML
